Stock Traders Purchase High Volume of Recursion Pharmaceuticals Call Options (NASDAQ:RXRX)

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) was the recipient of unusually large options trading activity on Wednesday. Traders bought 30,719 call options on the stock. This represents an increase of approximately 87% compared to the typical volume of 16,400 call options.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on RXRX shares. Morgan Stanley set a $5.30 target price on Recursion Pharmaceuticals in a research report on Monday, August 17th. Wall Street Zen lowered Recursion Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Friday, July 17th. Needham & Company LLC reiterated a “buy” rating and issued a $8.00 target price on shares of Recursion Pharmaceuticals in a research note on Thursday, May 7th. Finally, JPMorgan Chase & Co. dropped their target price on shares of Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating on the stock in a research report on Thursday, April 30th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $8.06.

Recursion Pharmaceuticals Stock Performance

Shares of RXRX stock traded down $0.04 during mid-day trading on Wednesday, reaching $3.52. The stock had a trading volume of 7,629,576 shares, compared to its average volume of 18,196,465. The business’s fifty day moving average is $3.30 and its 200-day moving average is $3.35. The company has a current ratio of 5.03, a quick ratio of 5.03 and a debt-to-equity ratio of 0.01. The firm has a market cap of $1.88 billion, a price-to-earnings ratio of -3.38 and a beta of 1.03. Recursion Pharmaceuticals has a 1-year low of $2.77 and a 1-year high of $7.18.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Wednesday, August 5th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.01). The firm had revenue of $7.67 million for the quarter, compared to analyst estimates of $10.97 million. Recursion Pharmaceuticals had a negative return on equity of 50.41% and a negative net margin of 945.94%.During the same period last year, the firm earned ($0.41) EPS. On average, research analysts forecast that Recursion Pharmaceuticals will post -0.92 earnings per share for the current year.

Insider Activity at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 40,000 shares of Recursion Pharmaceuticals stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $3.96, for a total value of $158,400.00. Following the transaction, the director directly owned 6,218,287 shares of the company’s stock, valued at approximately $24,624,416.52. The trade was a 0.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Najat Khan sold 23,588 shares of the stock in a transaction on Friday, June 5th. The shares were sold at an average price of $3.58, for a total value of $84,445.04. Following the sale, the chief executive officer owned 2,175,796 shares of the company’s stock, valued at approximately $7,789,349.68. This represents a 1.07% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 131,937 shares of company stock valued at $478,874. 6.65% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its holdings in Recursion Pharmaceuticals by 18.6% in the 4th quarter. Vanguard Group Inc. now owns 47,187,759 shares of the company’s stock worth $192,998,000 after buying an additional 7,407,606 shares during the last quarter. Hsbc Holdings PLC raised its holdings in shares of Recursion Pharmaceuticals by 537.3% during the fourth quarter. Hsbc Holdings PLC now owns 818,316 shares of the company’s stock valued at $3,367,000 after acquiring an additional 689,903 shares during the last quarter. Lingotto Investment Management LLP lifted its position in shares of Recursion Pharmaceuticals by 34.2% in the fourth quarter. Lingotto Investment Management LLP now owns 4,931,057 shares of the company’s stock valued at $20,168,000 after acquiring an additional 1,255,980 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Recursion Pharmaceuticals in the first quarter worth approximately $7,370,000. Finally, Norges Bank purchased a new stake in shares of Recursion Pharmaceuticals during the fourth quarter worth approximately $23,473,000. 89.06% of the stock is owned by hedge funds and other institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.